On February 19, Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction of Pacific Edge’s laboratory operations in Pennsylvania, led a Contractor Advisory Committee (CAC) meeting, inviting an expert panel of urology professionals to discuss the value of using urine-based biomarker tests in the evaluation of hematuria.

CACs are typically convened ahead of developing new or substantially revised Medicare policy and the opinions expressed by the panel clearly endorsed the use of urine-based biomarkers as medically reasonable and necessary, and appropriate for coverage by Medicare.

A recording of the session is now available. We invite you to view it here.

Review our full news release.